Copeland Capital Management LLC Sells 2,201 Shares of Chemed Corporation $CHE

Key Points

• Copeland Capital Management LLC reduced its stake in Chemed Corporation by 1.5%, selling 2,201 shares and retaining a total of 146,834 shares worth approximately $71.5 million.
• CEO Kevin J. McNamara sold 3,000 shares for about $1.38 million, which marked a 3.02% reduction in his ownership, while Director George J. Walsh III increased his holdings by purchasing 200 shares.
• Analysts have recently adjusted their target prices for Chemed, with Bank of America lowering it to $595, while Jefferies Financial Group raised it to $550, indicating mixed outlooks for the stock.

Copeland Capital Management LLC trimmed its holdings in shares of Chemed Corporation (NYSE:CHE - Free Report) by 1.5% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 146,834 shares of the company's stock after selling 2,201 shares during the period. Chemed makes up 1.5% of Copeland Capital Management LLC's investment portfolio, making the stock its 17th largest holding. Copeland Capital Management LLC owned about 1.00% of Chemed worth $71,498,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of CHE. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Chemed by 17.6% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 1,382 shares of the company's stock worth $732,000 after buying an additional 207 shares in the last quarter. Versant Capital Management Inc lifted its holdings in shares of Chemed by 600.0% in the 1st quarter. Versant Capital Management Inc now owns 98 shares of the company's stock worth $60,000 after purchasing an additional 84 shares in the last quarter. NBC Securities Inc. bought a new position in shares of Chemed in the 1st quarter worth $513,000. Merit Financial Group LLC bought a new position in shares of Chemed in the 1st quarter worth $257,000. Finally, Whipplewood Advisors LLC lifted its holdings in shares of Chemed by 54.5% in the 1st quarter. Whipplewood Advisors LLC now owns 51 shares of the company's stock worth $31,000 after purchasing an additional 18 shares in the last quarter. 95.85% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, CEO Kevin J. Mcnamara sold 3,000 shares of the firm's stock in a transaction on Friday, September 26th. The stock was sold at an average price of $461.28, for a total transaction of $1,383,840.00. Following the completion of the sale, the chief executive officer directly owned 96,197 shares of the company's stock, valued at $44,373,752.16. This trade represents a 3.02% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director George J. Walsh III bought 200 shares of the firm's stock in a transaction dated Monday, August 4th. The shares were acquired at an average cost of $417.10 per share, with a total value of $83,420.00. Following the completion of the transaction, the director owned 3,523 shares in the company, valued at approximately $1,469,443.30. The trade was a 6.02% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders sold 13,162 shares of company stock valued at $5,677,511. 3.29% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on CHE shares. Bank of America cut their target price on Chemed from $610.00 to $595.00 and set a "buy" rating on the stock in a report on Wednesday, September 10th. Royal Bank Of Canada cut their target price on Chemed from $640.00 to $589.00 and set an "outperform" rating on the stock in a report on Thursday, July 31st. Oppenheimer cut their target price on Chemed from $650.00 to $580.00 and set an "outperform" rating on the stock in a report on Thursday, July 31st. Wall Street Zen lowered Chemed from a "buy" rating to a "hold" rating in a research report on Saturday, July 5th. Finally, Jefferies Financial Group raised shares of Chemed from a "hold" rating to a "buy" rating and lifted their price objective for the stock from $490.00 to $550.00 in a report on Tuesday, September 2nd. Four analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $578.50.

Chemed Price Performance

Shares of Chemed stock opened at $441.44 on Friday. Chemed Corporation has a 1 year low of $408.42 and a 1 year high of $623.60. The firm has a market cap of $6.43 billion, a PE ratio of 22.70, a P/E/G ratio of 2.56 and a beta of 0.43. The stock has a fifty day moving average price of $449.24 and a 200-day moving average price of $517.53.

Chemed (NYSE:CHE - Get Free Report) last announced its earnings results on Tuesday, July 29th. The company reported $4.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.02 by ($1.75). Chemed had a net margin of 11.56% and a return on equity of 25.83%. The business had revenue of $618.80 million for the quarter, compared to analysts' expectations of $650.60 million. During the same period in the prior year, the business earned $5.47 earnings per share. The company's revenue for the quarter was up 3.8% compared to the same quarter last year. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. As a group, equities analysts anticipate that Chemed Corporation will post 21.43 EPS for the current fiscal year.

Chemed Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, August 29th. Stockholders of record on Monday, August 11th were given a dividend of $0.60 per share. The ex-dividend date of this dividend was Monday, August 11th. This represents a $2.40 annualized dividend and a dividend yield of 0.5%. This is a boost from Chemed's previous quarterly dividend of $0.50. Chemed's payout ratio is 12.34%.

About Chemed

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.

Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Corporation (NYSE:CHE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.